Radiation Drugs-A Hot Topic.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 229, doi. 10.1002/ddr.21023
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2012 AND VI 73 AND IP 5
Results: 7
1
2
Evaluation of a DTPA Prodrug, C2E5 as an Orally Bioavailable Radionuclide Decorporation Agent.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 243, doi. 10.1002/ddr.21019
- By:
- Publication type:
- Article
3
Efficacy of a Novel Orally Administered Formulation of DTPA Tablets for Decorporating an Intravenously Injected Radionuclide: A Comparison with Intravenously Administered Licensed DTPA.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 290, doi. 10.1002/ddr.21022
- By:
- Publication type:
- Article
4
Optical Spectroscopy and Multivariate Analysis for Biodosimetry and Monitoring of Radiation Injury to the Skin.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 252, doi. 10.1002/ddr.21021
- By:
- Publication type:
- Article
5
Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 281, doi. 10.1002/ddr.21020
- By:
- Publication type:
- Article
6
Consequence Management: Medical Countermeasures.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 274, doi. 10.1002/ddr.21017
- By:
- Publication type:
- Article
7
Preclinical Toxicology, Pharmacology, and Efficacy of a Novel Orally Administered Diethylenetriaminepentaacetic acid ( DTPA) Formulation.
- Published in:
- Drug Development Research, 2012, v. 73, n. 5, p. 232, doi. 10.1002/ddr.21018
- By:
- Publication type:
- Article